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Abstract
Background. Chronic metabolic acidosis (CMA) in
normal adults results in complex endocrine and
metabolic alterations including growth hormone
(GH) insensitivity, hypothyroidism, hyperglucocorti-
coidism, hypoalbuminaemia and loss of protein stores.
Similar alterations occur in chronic renal failure, a
prototypical state of CMA. We evaluated whether
metabolic acidosis contributes to the endocrine and
metabolic alterations characteristic of end-stage renal
disease.
Methods. We treated 14 chronic haemodialysis
patients with daily oral Na-citrate for 4 weeks, yielding
a steady-state pre-dialytic plasma bicarbonate concen-
tration of 26.7mmol/l, followed by 4 weeks of equi-
molar Na-chloride, yielding a steady-state pre-dialytic
plasma bicarbonate of 20.2mmol/l.
Results. Blood pressure, body weight and dialysis
adequacy were equivalent in the two protocols. Na-
citrate treatment corrected CMA, improved GH
insensitivity, increased and normalized plasma free T3
concentration, and improved plasma albumin. Correc-
tion of CMA had no signiﬁcant effect on measured
cytokines (interleukin-1b and -6, tumour necrosis
factor-a) or acute phase reactants (C-reactive protein,
serum amyloid A, a2-macroglobulin).
Conclusion. CMA contributes to the derangements of
the growth and thyroid hormone axes and to
hypoalbuminaemia, but is not a modulator of systemic
inﬂammation in dialysis patients. Correcting CMA
may improve nutritional and metabolic parameters
and thus lower morbidity and mortality.
Keywords: albumin; dialysis; growth hormone; meta-
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Introduction
Chronic metabolic acidosis (CMA) in rats induces
protein catabolism through the ubiquitin–proteasome
pathway and glucocorticoids [1]. In humans, whole-
body leucine ﬂux studies have conﬁrmed increased
protein turnover during CMA [2]. Other hormones
besides glucocorticoids may be involved, because CMA
in rats induces lower serum insulin-like growth factor
(IGF) 1 and 2 levels, and a tendency for lower mRNA
levels of hepatic IGF and growth hormone (GH)
receptor [3]. In healthy adults, CMA suppresses
albumin synthesis, increases glucocorticoids levels and
urinary nitrogen excretion, and induces GH insensitiv-
ity [4,5]. Furthermore, it lowers levels of free thyroxin
(fT4) and tri-iodothyronine (fT3) in the presence of an
increased thyroid-stimulating hormone (TSH) and an
exaggerated response to thyrotropin (TRH) [6]. Thus,
CMA induces complex hormonal derangements that
may mediate the acidosis-induced loss of protein stores
including a negative nitrogen balance and a low serum
albumin.
Patients on haemodialysis commonly exhibit some
degree of metabolic acidosis and multiple hormonal
and metabolic derangements. In patients with chronic
renal insufﬁciency as well as dialysis patients, GH/IGF-
1 insensitivity is present, with higher GH levels due to
increased GH bursts and a prolonged half-life of GH
[7]. Conversely, IGF-1 serum levels are lower and its
half-life reduced in association with impaired metabolic
effects in dialysis patients [8]. The thyroid hormone axis
is also abnormal, with low plasma T3 and T4 levels, a
normal TSH and a blunted response to TRH [9].
Hypoalbuminaemia due to diminished synthetic rate
is common in uraemia, but the mechanism for this
ﬁnding is unknown. There appears to be an inﬂuence of
inﬂammation [10] and possibly acidosis since CMA can
suppress albumin synthesis [4], but the latter remains
controversial in haemodialysis patients [11–14].
Identifying a mechanism could be important because
hypoalbuminaemia is a major predictor of mortality in
these patients [15,16].
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We investigated whether and to what extent correc-
tion of metabolic acidosis in haemodialysis patients
would affect derangements in the GH/IGF-1 and
thyroid hormone axes, glucocorticoid activity and
serum albumin.
Subjects and methods
The study was performed at the Cantonal Hospital St Gallen,
Switzerland. The dialysis unit comprises a total of 59
haemodialysis patients. Eight patients were not available or
had central venous catheters; in the remaining 51 patients, we
assessed the degree of metabolic acidosis by arterial blood
gas (ABG) analyses, showing a mean pre-dialysis plasma
bicarbonate concentration of 19.9±0.7mmol/l. Of these
patients, 16 were found not suitable for enrolment due
to special transportation needs, ﬁve were recovering from
or scheduled for a surgical procedure, and four patients
were excluded due to serious co-morbid conditions.
Of the remaining 26 patients, 14 (nine men, ﬁve women)
agreed to be enrolled in the study and received compensation.
ABGs revealed a pre-dialysis plasma bicarbonate of
19.1±1.9mmol/l in the 14 study participants, and
20.2±2.5mmol/l in the 37 non-participants.
Patients were instructed to maintain their usual diet and
daily activities throughout the study; concomitant medica-
tions were not changed. All patients were dialysed three times
weekly at a dialysate bicarbonate concentration of 32mmol/l.
Equilibrated dual-pool dialysis dose (eKt/V) and normalized
protein catabolic rate (nPCR) were calculated using well
established formulae.
The study lasted 56 days and was divided into two sequ-
ential experimental periods lasting 29 and 27 days (Figure 1).
First, a prescribed amount of Na-citrate was adjusted to
achieve a pre-dialytic plasma bicarbonate of 24–26mmol/l as
guided by thrice weekly ﬁstula-derived pre-dialytic ABG
values (accepted if pO2 was >65mmHg; mean±SD 81.3±
9.6mmHg, n¼ 138). In the second period, the subjects
received an equimolar amount of Na-chloride. The ﬁnal daily
doses were 1.13±0.10mmol/kg for Na-citrate and 1.10±
0.08mmol/kg for Na-chloride. Both were taken as gelatin
capsules and were well tolerated. We investigated the GH/IGF-
1 axis by administration of GH and growth hormone-releasing
hormone (GHRH) as shown in Figures 3–7.
Except for ABGs, all serum samples were immediately
placed on ice and stored at 70C until analysed. GH mea-
surements were assayed by immunoassay (CLIA; Immulite,
Diagnostic Products Corporation). IGF-1, free IGF-1 and
IGF-binding protein 3 (BP3) samples were assayed by
immuno-radiometry (DSL-2800, DSL-9400, DSL-6600;
Diagnostic Systems Laboratory), measured on a gamma-
counter (1261 Multigamma, Wallac) and calculated using a
log–log ﬁtting algorithm with the Riacalc Software (Wallac).
GH half-life (t1/2) and metabolic clearance rate (MCR) were
calculated comparing slopes (k) between 50 and 120min,
adjusted to the same plasma concentrations. Using t1/2¼
1/k ln0.5, and k¼ [ln (ct/co)/t], we calculated MCR as
Vd (ln2/t1/2), where t signiﬁes the individual time points, co
and ct the concentration of GH at time 0 and t, and Vd the
estimated volume of distribution of GH [7]. Serum TSH and
fT4, fT3 were measured using microparticle enzyme immu-
noassay (AxSym, Abbott), reverse T3 by radioimmunoassy
(Laboratoires Serono), lipoprotein (a) [Lp(a)], serum albu-
min and a2-macroglobulin (a-MG) by immune nephelometry
(BN lI, Dade Behring), insulin and c-peptide by CLIA
(Immulite), C-reactive protein (CRP) by an immunoturbidi-
metric assay, and interleukin (IL)-1b, -6 and -13, and tumour
necrosis factor-a (TNF-a) by enzyme-linked immunosorbent
assay (ELISA; Quantikin RD Systems and Endogen).
All results are expressed as mean±SD unless noted
otherwise. Statistical analysis was determined by Student’s
two-tailed t-test for paired data. The institutional ethics
committee approved the study.
Results
Average patient age was 52.4 years (range 29–79), and
mean time on dialysis was 33 months (range 6–109).
The patients were well nourished with a lean body mass
of 74% for men and 70% for women (by DEXA), an
average body mass index of 22.1 kg/m2, and an average
weight change of only 0.7% over the preceding 6
months. Of the 14 patients, one left the study at the
end of the Na-chloride time period; the remaining 13
completed the study.
Effect of acidosis correction on body weight, acid–base,
electrolytes and nutrition
Pre- and post-dialysis body weights and blood pressure
readings were no different between the Na-chloride and
Na-citrate periods (Table 1). Administration of Na-
citrate for 3 weeks normalized acid–base status without
inducing hypoxaemia, while equimolar Na-chloride
over the same time period induced metabolic acidosis
(Figure 2, Table 1). Blood gases obtained immediately
at the end of a dialysis session revealed no difference in
HCO3
– or pH between the Na-citrate and Na-chloride
period (Figure 2). We found that plasma chloride,
potassium and ionized calcium concentrations were
higher, nPCR and pre-albumin were unchanged, and
albumin was lower during acidosis (Table 1). Dialysis
adequacy (eKt/V) remained the same (1.25þ 0.21 vs
1.22þ 0.29, P¼ 0.51).
Effect of acidosis correction on plasma hormone
concentrations
During CMA induced by Na-chloride, fT3 concentra-
tions were lower than during Na-citrate administration
in each subject (P<0.001), but reverse T3, fT4 and TSH
were similar (Table 1).
Stimulation of endogenous IGF-1 by GH injected
at 0, 12 and 24 h provoked a rapid rise of plasma total
and free IGF-1, and, after a brief delay, of IGF-BP3.
Although the total IGF-1 response to GH administra-
tion was not different for the two time periods, free
IGF-1 was higher and IGF-BP3 lower with Na-citrate
compared with the period with CMA (Figures 3–5).
In parallel to the rise in IGF-1 after stimulation by
GH, we observed a rapid rise in c-peptide levels. The
area under the curve (AUC) for c-peptide was higher
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during Na-citrate compared with Na-chloride (Figure
6); glucose levels did not rise in either period. There was
no difference between fasting insulin (AUC 21.6±2.6
vs 24.2±4.1U h/l, P¼ 0.50) or fasting plasma
glucose levels (AUC 8.3±0.3 vs 8.0±0.5mmol h/l).
The GH response to GHRH between 0 and 45min
(before octreotide) was not different during Na-citrate
vs Na-chloride administration. However, the endogen-
ous MCR for GH was reduced and, correspondingly,
its half-life prolonged during CMA, as measured after
octreotide administration to inhibit endogenous GH
production (Figure 7).
Effect of correction of CMA on cytokines and
acute phase reactants
Plasma levels of IL-1b, IL-6 and TNF-a and the acute
phase reactants CRP and serum amyloid A (SAA) were
all increased (Table 2). In contrast, acute phase
reactants Lp(a) and a-MG were normal. Correction
of acidosis by supplementing with Na-citrate did
not alter the cytokine and acute phase reactant proﬁle,
with the exception of a decrease in plasma Lp(a)
concentration (P¼ 0.04).
Discussion
Our data indicate that some metabolic abnormalities
associated with chronic renal failure and dialysis are at
least partially associated with metabolic acidosis. More
importantly, these defects can be partially corrected by
giving Na-citrate. We found that CMA in dialysis
patients contributes to low fT3 and to GH insensitivity.
CMA is also associated with lower levels of serum
albumin. In contrast, the cytokine and acute
phase reactant expression proﬁle so typical of uraemia
was not affected by CMA, suggesting that CMA
suppresses albumin as well as the thyroid and GH axes
independently of inﬂammation.
Protein metabolism and nutritional parameters
We found a signiﬁcantly higher serum albumin during
Na-citrate therapy compared with Na-chloride, deter-
mined both by routine chemistry assay and by
nephelometry (Table 1). Other investigators have not
found signiﬁcant effects of acidosis correction on
albumin levels [12], but their studies were either cross-
sectional or did not add a comparable amount of
neutral anions to the control group to correct for
possible volume effects of base supplementation.
An association of CMA with hypoalbuminaemia is
Table 1. Pre-dialytic vital signs, electrolytes and acid–base
Parameter (n¼ 13) Na-citrate Na-chloride t-test
mean±SD mean±SD P-value
Vitals
Pre-dialysis weight (kg) 66.3±18.1 65.9±17.8 0.10
Post-dialysis weight (kg) 63.7±17.7 63.3±17.8 0.18
Interdialytic weight  3.4±1.3 3.4±1.2 0.78
Blood pressure (mmHg)
Systolic/diastolic 157/86±20/10 156/85±20/11 0.87/0.53
Mean 110±13 109±13 0.73
Electrolytes (mmol/l)
Naþ (130–145) 141±3 139±3 0.09
Cl (95–107) 98±3 105±2 <0.001
Kþ (3.6–4.8) 5.3±0.7 5.6±0.8 0.008
Ca2þ(1.0–1.25) 1.08±0.09 1.20±0.16 0.007
Arterial blood gas
pH 7.44±0.01 7.32±0.05 <0.001
HCO3
 (mmol/l) 26.1±0.4 20.4±2.2 <0.001
pCO2 (mmHg) 38.1±2.3 33.8±2.3 <0.001
pO2 (mmHg) 79.2±6.5 84.2±9.7 0.010
Nutrition
nPCR (g/kg/day) 1.18±0.30 1.09±0.43 0.17
Pre-albumin (mg/dl)
(21–41)
35.7±4.8 34.4±4.6 0.28
Albumin (neph) (mg/dl)
(3.7–5.3)
4.02±0.28 3.82±0.29 0.01
Albumin (chem) (mg/dl)
(3.4–4.8)
4.1±0.26 3.7±0.35 0.01
Thyroid hormone axis
Free T3 (pmol/l)
(2.5–5.7)
3.1±0.42 2.3±0.55 <0.001
Reverse T3 (pmol/l)
(150–540)
287±137 236±205 0.18
Free T4 (pmol/l) (9–24) 11.6±1.7 11.1±1.4 0.38
TSH (mU/l) (0.25–4) 1.30±0.85 1.38±0.77 0.60
Neph¼nephelometric assay; chem¼ chemistry assay. Normal
range in parentheses.
Fig. 1. Study protocol. Arrows: GH, 30mg/kg body weight of GH subcutaneously at time 0, 12 and 24 h with measurements of glucose,
insulin, c-peptide, IGF-1 and IGF-BP3 (Figures 3–6); GHRH, 0.1 mg/kg body weight of GHRH intravenously with measurement of GH,
and octreotide 50mg intravenously plus 50 mg subcutaneously (100mg if body weight >60kg) given at 45min (Figure 7). Bars:
measurements of electrolytes and parameters of nutrition, inﬂammation and dialysis (Tables 1 and 2).
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Fig. 2. Comparison of blood bicarbonate levels at different time points in relation to dialysis. HCO3
 immediately after dialysis (‘post’)
was 27.5±0.5 during Na-citrate and 26.6±0.5mmol/l during Na-chloride (black bars); 2 h later, 26.5±0.5 and 24.2±0.7mmol/l (P¼ 0.02;
grey bars), and pre-dialysis (‘48 h post’) 26.1±0.4 and 20.4±2.2mmol/l (P<0.001, light bars), respectively. #P<0.001 for pH, pO2, HCO3

comparison Na-citrate vs Na-chloride. *P¼ 0.02 for pH and HCO3 comparison Na-citrate vs Na-chloride. Paired t-test (n¼ 14).
Means±SE.
Fig. 3. Time course of total IGF-1 after administration of GH. The AUC is 568±63mgh/l for Na-citrate (open circles, dashed lines) and
560±68mgh/l for Na-chloride (solid lines and circles). P¼ 0.64, paired t-test (n¼ 13). Means±SE.
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Fig. 4. Time course of IGF-BP3 after administration of GH. The AUC is 7.26±0.30mgh/l for Na-citrate (open circles, dashed lines) and
7.58±0.34mgh/l for Na-chloride (solid lines and circles). P¼ 0.03, paired t-test (n¼ 13). Means±SE.
Fig. 5. Time course of free IGF-1 after administration of GH. The AUC is 3.08±0.42mgh/l for Na-citrate (open circles, dashed lines)
and 2.57±0.37mgh/l for Na-chloride (solid lines and circles). P¼ 0.001, paired t-test (n¼ 13). Means±SE. *P<0.05 for mean values.
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Fig. 7. Time course of GH after administration of GHRH and octreotide. The AUC between 0 and 45min (before octreotide) is
13.7±2.4mgmin/l for Na-citrate (open circles) and 16.0±4.6mgmin/l for Na-chloride (solid circles) time periods (P¼ 0.57). The half-
life is longer (30.2±0.8 vs 28.1±0.6min, P¼ 0.02) and metabolic clearance rate lower (72.7±2.0 vs 78.3±1.6ml/minm2, P¼ 0.01)
during Na-chloride, measured during octreotide. Paired t-test (n¼ 14). Means±SE.
Fig. 6. Time course of free c-peptide after administration of GH. The AUC is 7.90±0.83 nmolh/l for Na-citrate (open circles, dashed
lines) and 6.86±0.77 nmolh/l for Na-chloride (solid lines and circles). P¼ 0.046, paired t-test (n¼ 13). Means±SE. *P<0.01 for mean
values.
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consistent with an earlier prospective study of haemo-
dialysis patients, in which plasma albumin increased
with correction of CMA [14]. Our study extends this
report by adding a control period using equimolar Na-
chloride supplementation during CMA. The choice of
equimolar oral Na-chloride control to mimic the
chronic extracellular ﬂuid volume (ECV) expansion of
Na-citrate was based on both human and animal data,
showing a similar increase of ECV and plasma volume
on either salt. We did not measure ECV in this study.
However, pre-dialysis weights and interdialytic weight
gain, as well as blood pressure values remained very
stable during both time periods, as illustrated in Table 1.
Therefore, it is unlikely that there is any signiﬁcant
confounding inﬂuence of ECV expansion. Finally, to
ensure steady-state conditions and adequate expo-
sure to each sodium salt, at least 21 (Na-citrate) or 23
(Na-chloride) days were required before assessing
laboratory parameters. A carry-over effect from the
Na-citrate period to the Na-chloride period is possible,
but, if present, would only minimize the difference
between Na-chloride and Na-citrate administration.
Serum albumin is a complex parameter inﬂuenced by
both protein intake (nutrition), and albumin synthesis
and degradation, the latter reﬂecting its role as an acute
phase protein. Since the cytokine and acute phase
reactant proﬁle was not altered by acidosis [except for
Lp(a)], we believe that the lower albumin concentration
observed during Na-chloride supplementation is not a
direct consequence of an enhanced inﬂammatory state.
While the difference observed is quite small (4.0 vs
3.8 g/dl), there is a direct and linear correlation between
serum albumin levels and mortality in haemodialysis
patients; a level of 3.7 vs 4.0 g/dl constitutes a diff-
erence, as just recently shown [16]. Na-citrate supple-
mentation beyond the 4 weeks used in our study would
possibly have an even greater impact.
Endocrine analysis
Uraemic patients demonstrate complex thyroid dys-
function characterized by markedly depressed levels of
T3 and lower (but still normal) T4 with a normal TSH,
a decreased thyroid response to exogenous TSH, a
blunted TSH release to TRH, as well as decreased
peripheral conversion of T4 to T3 [9]. In normal adults,
we found that induction of CMA caused reduced serum
levels of fT4 and fT3 and a physiological rise in TSH,
suggesting a primary intrathyroidal hormonal secretory
defect [6]. In ESRD patients, our ﬁndings conﬁrm
thyroid dysfunction in uraemia, but furthermore show
that plasma fT3 can be fully corrected by eliminating
CMA.
Low levels of plasma free IGF-1 are present in both
(non-uraemic) CMA and renal failure patients, and
are believed to signal the presence of malnutrition in
haemodialysis patients (4,17). CMA plays an important
role because the free IGF-1 response improved by
supplementing with Na-citrate and because similar
results occur in normal adults with CMA [5]. Post-
dialysis plasma levels of IGF-1 and GH are similar in
both experimental time periods. However, progressive
acidosis within each interdialytic cycle occurs only
during administration of Na-chloride. Free IGF-1
levels are therefore expected to be lowest during
maximum acidosis, i.e. pre-dialysis, when GH is
expected to be highest due to loss of negative feedback
inhibition by IGF-1. The difference in acid–base status
among the two groups became greater during the
experiment, and, correspondingly, there is progressive
acidosis-related attenuation of plasma free IGF-1 after
GH infusion, as illustrated in Figure 5. We could not
ﬁnd a signiﬁcant difference in the plasma GH response
after GHRH infusion, but demonstrated a diminished
metabolic clearance rate and prolonged half-life of GH
during acidosis.
While insulin levels after GH stimulation were no
different for both time periods, we found an attenuated
increase in c-peptide during acidosis despite compar-
able plasma glucose levels. C-peptide is a better marker
of insulin secretion because of its greater stability and
less variable clearance. Correction of metabolic acido-
sis in uraemia leads to both increased insulin sensitivity
and insulin secretion, as measured by euglycaemic and
hyperglycaemic clamp studies [18].
Metabolic acidosis has proteolytic effects and leads
to increased cortisol secretion in normal subjects [4].
Glucocorticoids also appear to be necessary mediators
of protein catabolism [1]. We did not ﬁnd a difference in
the plasma cortisol levels between the Na-chloride and
Na-citrate treatments (data not shown), and we cannot
comment on the role of glucocorticoids in proteolysis
in haemodialysis patients. Notably, others have found
that correction of metabolic acidosis suppresses
whole-body protein degradation in these patients [13].
Inﬂammatory response
Acute phase reactants such as CRP, a2-MG, SAA, and
the cytokines IL-1b, IL-6 and TNF-a are reported to be
elevated in patients on long-term haemodialysis. These
markers of inﬂammation have been correlated with
hypoalbuminaemia, but it is not known whether the
inﬂammatory response is related to acidosis. Except for
normal serum levels for a2-MG and Lp(a), our results
Table 2. Cytokines and acute phase reactants
Parameter Normal Na-citrate
mean±SD
Na-chloride
mean±SD
Paired
t-test
P-value
Cytokines
IL-1b (pg/ml) (7) <0.1 9.3±10.7 7.8±8.8 0.16
IL-6 (pg/ml) (13) <3.1 3.6±2.2 4.4±5.6 0.58
TNF-a (pg/ml) (5) <6.3 7.4±6.4 6.4±4.5 0.57
Acute phase reactants
CRP (mg/l) (11) <5 8.0±4.8 12.2±17.5 0.45
SAA (mg/l) (13) <6.4 17±23 32±94 0.51
a2-MG (g/l) (12) 1.3–3.0 1.8±0.7 1.7±0.7 0.18
Lp(a) (mg/l) (11) <300 116±113 131±130 0.04
Values in parentheses are number of measurements available.
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conﬁrm a cytokine expression proﬁle typical of dialysis
patients. While correcting acidosis did not change these
markers of inﬂammation, it was associated with a
higher serum albumin level. This suggests an indepen-
dent effect of acidosis on albumin levels, and, hence,
provides additional information that the mechanisms
for hypoalbuminaemia in kidney failure patients are
more complex than a reﬂection of an inadequate diet.
Lp(a) is an acute phase reactant that is structurally
similar to LDL and represents a cardiovascular risk
factor in haemodialysis patients. We found that the
Lp(a) concentration was greater during CMA, possibly
reﬂecting GH insensitivity, since IGF-1 administration
decreases plasma Lp(a) in normal adults [19]. Correc-
tion of acidosis may therefore lower Lp(a) levels and
improve cardiovascular risk.
In summary, we ﬁnd that acidosis is responsible for
some of the endocrine derangements found in chronic
haemodialysis patients. Dialysate bicarbonate concen-
tration can be safely increased from 36 to 42meq/l and
will correct metabolic acidosis in 75% of patients
without progressive alkalaemia, hypoxia or hypercar-
bia [20], and Na-alkali therapy can be given between
dialysis sessions with minimal or no complications. It is
conceivable that this strategy will improve abnormal-
ities in protein metabolism, endocrine status and
possibly long-term outcome of haemodialysis therapy.
Conﬂict of interest statement. None declared.
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